Literature DB >> 10986679

Self-administered topical imiquimod treatment of vulvar intraepithelial neoplasia. A report of four cases.

G Davis1, J Wentworth, J Richard.   

Abstract

BACKGROUND: Vulvar intraepithelial neoplasia (VIN) generally can be classified into viral and nonviral etiologies. The histopathologic diagnosis is often separable into basaloid and warty types. A large percentage of VIN lesions have been shown to harbor human papillomavirus (HPV), principally type 16. Imiquimod, an immune response modifier, has been shown to be safe and effective for the treatment of external and perianal genital warts caused by HPV. CASES: Four cases occurred of clinical and histopathologically diagnosed viral VIN 3. An imiquimod treatment protocol, previously used in a study of this drug for the treatment of external genital warts, was followed. Imiquimod 5% cream was patient applied three times per week until all lesions cleared, for a maximum of 16 weeks.
CONCLUSION: Imiquimod may be an effective treatment modality for viral VIN 3 in the future.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10986679

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  4 in total

Review 1.  Genital warts treatment: Beyond imiquimod.

Authors:  Jianwei Yuan; Guoying Ni; Tianfang Wang; Kate Mounsey; Shelley Cavezza; Xuan Pan; Xiaosong Liu
Journal:  Hum Vaccin Immunother       Date:  2018-04-09       Impact factor: 3.452

2.  Malignant conversion of florid oral and labial papillomatosis during topical immunotherapy with imiquimod.

Authors:  K Wenzel; B Saka; R Zimmermann; K K H Gundlach; M Barten; G Gross
Journal:  Med Microbiol Immunol       Date:  2003-04-29       Impact factor: 3.402

3.  Non-responders to topical imiquimod followed by vaccination therapy in VIN patients may be due to the level of IL10.

Authors:  X S Liu
Journal:  Br J Cancer       Date:  2010-07-27       Impact factor: 7.640

4.  Recurrence of vulval intraepithelial neoplasia following treatment with cidofovir or imiquimod: results from a multicentre, randomised, phase II trial (RT3VIN).

Authors:  C N Hurt; Sef Jones; T-A Madden; A Fiander; A J Nordin; R Naik; N Powell; M Carucci; A Tristram
Journal:  BJOG       Date:  2018-02-09       Impact factor: 6.531

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.